STAAR Surgical announced preliminary net sales for Q2 2026 are expected to exceed $90 million, a significant increase from $44.3 million in Q2 2025. This substantial year-over-year growth indicates strong performance and could lead to a positive market reaction when official earnings are released.
STAAR Surgical reported preliminary Q2 2026 net sales exceeding $90 million, more than doubling the $44.3 million from Q2 2025. This significant growth indicates robust demand for their EVO ICL products and strong operational execution. This news is highly positive for STAA, as it suggests the company is outperforming expectations and could lead to upward revisions in analyst forecasts. Traders should anticipate a positive short-term reaction to this news, with potential for continued long-term growth if this sales momentum is sustained. The key opportunity for traders is to capitalize on the likely upward price movement following this strong preliminary announcement.